ABPP methodology: Introduction and overview

Topics in Current Chemistry

Volumn 324, Issue , 2012, Pages 1-41

  Nodwell, Matthew B ^a   Sieber, Stephan A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Activity based protein profiling; Analytical chemistry; Chemical biology; Proteomics

Indexed keywords

PROTEIN; PROTEOME;

CHEMISTRY; HUMAN; MOLECULAR PROBE; PROTEIN MICROARRAY; PROTEOMICS; REVIEW;

HUMANS; MOLECULAR PROBES; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOME; PROTEOMICS;

EID: 84857774303     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128_2011_302     Document Type: Review

References (195)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
2. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799 (Pubitemid 39070849)
3. Kobe B, Kemp BE (1999) Active site-directed protein regulation. Nature 402:373-376 (Pubitemid 129544817)
4. Walsh CT (2006) Posttranslational modification of proteins: expanding nature's inventory. Roberts, Englewood, CO
5. Gygi SP, Rist B, Gerber SA et al (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17:994-999 (Pubitemid 29474856)
6. Washburn MP, Wolters D, Yates JR 3rd (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19:242-247 (Pubitemid 32220565)
7. Zhu H, Bilgin M, Snyder M (2003) Proteomics. Annu Rev Biochem 72:783-812 (Pubitemid 36930460)
8. Ito T, Ota K, Kubota H et al (2002) Roles for the two-hybrid system in exploration of the yeast protein interactome. Mol Cell Proteomics 1:561-566
9. MacBeath G (2002) Protein microarrays and proteomics. Nat Genet 32(Suppl):526-532 (Pubitemid 35435157)
10. Evans MJ, Cravatt BF (2006) Mechanism-based profiling of enzyme families. Chem Rev 106:3279-3301 (Pubitemid 44376936)
11. Heal WP, Dang TH, Tate EW (2011) Activity-based probes: discovering new biology and new drug targets. Chem Soc Rev 40:246-257
12. Cravatt BF, Wright AT, Kozarich JW (2008) Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu Rev Biochem 77:383-414
13. Bottcher T, Pitscheider M, Sieber SA (2010) Natural products and their biological targets: proteomic and metabolomic labeling strategies. Angew Chem Int Ed Engl 49:2680-2698
14. Barglow KT, Cravatt BF (2007) Activity-based protein profiling for the functional annotation of enzymes. Nat Methods 4:822-827 (Pubitemid 350055579)
15. Dennehy MK, Richards KA, Wernke GR et al (2006) Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol 19:20-29 (Pubitemid 43185458)
16. Scaloni A, Ferranti P, De Simone G et al (1999) Probing the reactivity of nucleophile residues in human 2,3-diphosphoglycerate/deoxy-hemoglobin complex by aspecific chemical modifications. FEBS Lett 452:190-194 (Pubitemid 29301742)
17. Slaughter DE, Hanzlik RP (1991) Identification of epoxide-and quinone-derived bromobenzene adducts to protein sulfur nucleophiles. Chem Res Toxicol 4:349-359
18. Rando RR (1977) Mechanism-based irreversible enzyme inhibitors. Methods Enzymol 46:28-41
19. Drahl C, Cravatt BF, Sorensen EJ (2005) Protein-reactive natural products. Angew Chem Int Ed Engl 44:5788-5809 (Pubitemid 41316844)
20. Pitscheider M, Sieber SA (2009) Cinnamic aldehyde derived probes for the active site labeling of pathogenesis associated enzymes. Chem Commun 2009:3741-3743
21. Weerapana E, Simon GM, Cravatt BF (2008) Disparate proteome reactivity profiles of carbon electrophiles. Nat Chem Biol 4:405-407 (Pubitemid 351860548)
22. Evans MJ, Saghatelian A, Sorensen EJ et al (2005) Target discovery in small-molecule cellbased screens by in situ proteome reactivity profiling. Nat Biotechnol 23:1303-1307 (Pubitemid 41486859)
23. Robinette D, Neamati N, Tomer KB et al (2006) Photoaffinity labeling combined with mass spectrometric approaches as a tool for structural proteomics. Expert Rev Proteomics 3:399-408 (Pubitemid 44231983)
24. Tanaka Y, Bond MR, Kohler JJ (2008) Photocrosslinkers illuminate interactions in living cells. Mol Biosyst 4:473-480 (Pubitemid 351706286)
25. Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist's guide to molecular interactions. J Med Chem 53:5061-5084
26. Rostovtsev VV, Green LG, Fokin VV et al (2002) A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl 41:2596-2599 (Pubitemid 34803480)
27. Meldal M, Tornoe CW (2008) Cu-catalyzed azide-alkyne cycloaddition. Chem Rev 108:2952-3015
28. Speers AE, Adam GC, Cravatt BF (2003) Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3+2] cycloaddition. J Am Chem Soc 125:4686-4687 (Pubitemid 36505343)
29. Saxon E, Bertozzi CR (2000) Cell surface engineering by a modified Staudinger reaction. Science 287:2007-2010 (Pubitemid 30158675)
30. Kohn M, Breinbauer R (2004) The Staudinger ligation-a gift to chemical biology. Angew Chem Int Ed Engl 43:3106-3116 (Pubitemid 39257599)
31. Agard NJ, Prescher JA, Bertozzi CR (2004) A strain-promoted [3+2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc 126:15046-15047 (Pubitemid 39557262)
32. Beatty KE, Fisk JD, Smart BP et al (2010) Live-cell imaging of cellular proteins by a strainpromoted azide-alkyne cycloaddition. Chembiochem 11:2092-2095
33. Codelli JA, Baskin JM, Agard NJ et al (2008) Second-generation difluorinated cyclooctynes for copper-free click chemistry. J Am Chem Soc 130:11486-11493
34. Amara N, Mashiach R, Amar D et al (2009) Covalent inhibition of bacterial quorum sensing. J Am Chem Soc 131:10610-10619
35. Liu S, Zhou B, Yang H et al (2008) Aryl vinyl sulfonates and sulfones as active site-directed and mechanism-based probes for protein tyrosine phosphatases. J Am Chem Soc 130:8251-8260 (Pubitemid 351898544)
36. Adam GC, Sorensen EJ, Cravatt BF (2002) Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat Biotechnol 20:805-809 (Pubitemid 34836757)
37. Patricelli MP, Giang DK, Stamp LM et al (2001) Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 1:1067-1071 (Pubitemid 33696471)
38. Liu Y, Patricelli MP, Cravatt BF (1999) Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci USA 96:14694-14699 (Pubitemid 30019702)
39. Kidd D, Liu Y, Cravatt BF (2001) Profiling serine hydrolase activities in complex proteomes. Biochemistry 40:4005-4015 (Pubitemid 32280438)
40. Santoni V, Molloy M, Rabilloud T (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis 21:1054-1070 (Pubitemid 30230772)
41. Corthals GL, Wasinger VC, Hochstrasser DF et al (2000) The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21:1104-1115 (Pubitemid 30230776)
42. Bottcher T, Sieber SA (2010) Showdomycin as a versatile chemical tool for the detection of pathogenesis-associated enzymes in bacteria. J Am Chem Soc 132:6964-6972
43. Tully SE, Cravatt BF (2010) Activity-based probes that target functional subclasses of phospholipases in proteomes. J Am Chem Soc 132:3264-3265
44. Jessani N, Niessen S, Wei BQ et al (2005) A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods 2:691-697 (Pubitemid 41223096)
45. Liu H, Sadygov RG, Yates JR 3rd (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76:4193-4201 (Pubitemid 38943698)
46. Old WM, Meyer-Arendt K, Aveline-Wolf L et al (2005) Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 4:1487-1502 (Pubitemid 41555475)
47. Adam GC, Burbaum J, Kozarich JW et al (2004) Mapping enzyme active sites in complex proteomes. J Am Chem Soc 126:1363-1368 (Pubitemid 38200806)
48. Okerberg ES, Wu J, Zhang B et al (2005) High-resolution functional proteomics by activesite peptide profiling. Proc Natl Acad Sci USA 102:4996-5001
49. Speers AE, Cravatt BF (2005) A tandem orthogonal proteolysis strategy for high-content chemical proteomics. J Am Chem Soc 127:10018-10019 (Pubitemid 40995443)
50. Sieber SA, Mondala TS, Head SR et al (2004) Microarray platform for profiling enzyme activities in complex proteomes. J Am Chem Soc 126:15640-15641 (Pubitemid 39602413)
51. Kodadek T (2001) Protein microarrays: prospects and problems. Chem Biol 8:105-115 (Pubitemid 32296105)
52. Winssinger N, Ficarro S, Schultz PG et al (2002) Profiling protein function with small molecule microarrays. Proc Natl Acad Sci USA 99:11139-11144 (Pubitemid 34920892)
53. Clark JD, Schievella AR, Nalefski EA et al (1995) Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 12:83-117
54. Mignatti P, Rifkin DB (1996) Plasminogen activators and angiogenesis. Curr Top Microbiol Immunol 213(Pt 1):33-50 (Pubitemid 26165085)
55. DeClerck YA, Imren S, Montgomery AM et al (1997) Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 425:89-97 (Pubitemid 128701763)
56. Gorrell MD (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108:277-292 (Pubitemid 40516992)
57. Walsh CT (1979) Enzymatic reaction mechanisms. W.H. Freeman, New York
58. Powers JC, Asgian JL, Ekici OD et al (2002) Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 102:4639-4750
59. Bouma BN, Miles LA, Beretta G et al (1980) Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 19:1151-1160 (Pubitemid 10033197)
60. Jessani N, Humphrey M, McDonald WH et al (2004) Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 101:13756-13761 (Pubitemid 39298480)
61. Jessani N, Liu Y, Humphrey M et al (2002) Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci USA 99:10335-10340
62. Mahrus S, Craik CS (2005) Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 12:567-577 (Pubitemid 40727931)
63. Gelb BD, Shi GP, Chapman HA et al (1996) Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238
64. Sloane BF, Yan S, Podgorski I et al (2005) Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol 15:149-157 (Pubitemid 40126246)
65. Yan S, Sameni M, Sloane BF (1998) Cathepsin B and human tumor progression. Biol Chem 379:113-123 (Pubitemid 28075970)
66. Shenai BR, Sijwali PS, Singh A et al (2000) Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J Biol Chem 275:29000-29010
67. Iwata Y, Mort JS, Tateishi H et al (1997) Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum 40:499-509 (Pubitemid 27123666)
68. Barrett AJ, Kembhavi AA, Brown MA et al (1982) L-trans-Epoxysuccinyl- leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 201:189-198 (Pubitemid 12038477)
69. Barrett AJ, Kembhavi AA, Hanada K (1981) E-64 [L-trans-epoxysuccinyl- leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. Acta Biol Med Ger 40:1513-1517 (Pubitemid 12022366)
70. Palmer JT, Rasnick D, Klaus JL et al (1995) Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 38:3193-3196
71. Shaw E (1994) Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. Methods Enzymol 244:649-656
72. Shaw E, Angliker H, Rauber P et al (1986) Peptidyl fluoromethyl ketones as thiol protease inhibitors. Biomed Biochim Acta 45:1397-1403 (Pubitemid 17018569)
73. Pliura DH, Bonaventura BJ, Smith RA et al (1992) Comparative behaviour of calpain and cathepsin B toward peptidyl acyloxymethyl ketones, sulphonium methyl ketones and other potential inhibitors of cysteine proteinases. Biochem J 288(Pt 3):759-762 (Pubitemid 23031752)
74. Fonovic M, Bogyo M (2007) Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. Curr Pharm Des 13:253-261 (Pubitemid 46085277)
75. Brady KD, Giegel DA, Grinnell C et al (1999) A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones. Bioorg Med Chem 7:621-631 (Pubitemid 29150305)
76. Dai Y, Hedstrom L, Abeles RH (2000) Inactivation of cysteine proteases by (acyloxy)methyl ketones using S0-P0 interactions. Biochemistry 39:6498-6502 (Pubitemid 30347156)
77. Kato D, Boatright KM, Berger AB et al (2005) Activity-based probes that target diverse cysteine protease families. Nat Chem Biol 1:33-38
78. Mitic N, Smith SJ, Neves A et al (2006) The catalytic mechanisms of binuclear metallohydrolases. Chem Rev 106:3338-3363 (Pubitemid 44376939)
79. Whittaker M, Floyd CD, Brown P et al (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99:2735-2776
80. Skiles JW, Gonnella NC, Jeng AY (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 8:425-474 (Pubitemid 32409788)
81. Hooper NM, Turner AJ (2002) The search for alpha-secretase and its potential as a therapeutic approach to Alzheimer s disease. Curr Med Chem 9:1107-1119 (Pubitemid 34568187)
82. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157-166 (Pubitemid 34309470)
83. Sierevogel MJ, Pasterkamp G, de Kleijn DP et al (2003) Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 9:1033-1040 (Pubitemid 36443205)
84. Sieber SA, Niessen S, Hoover HS et al (2006) Proteomic profiling of metalloprotease activities with cocktails of active-site probes. Nat Chem Biol 2:274-281
85. Saghatelian A, Jessani N, Joseph A et al (2004) Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci USA 101:10000-10005 (Pubitemid 38891185)
86. Chan EW, Chattopadhaya S, Panicker RC et al (2004) Developing photoactive affinity probes for proteomic profiling: hydroxamate-based probes for metalloproteases. J Am Chem Soc 126:14435-14446 (Pubitemid 39463627)
87. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51 (Pubitemid 43054973)
88. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784 (Pubitemid 44348499)
89. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90 (Pubitemid 46087907)
90. Salisbury CM, Cravatt BF (2007) Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci USA 104:1171-1176 (Pubitemid 46183977)
91. Overkleeft HS et al. (2012) Photoaffinity labeling in activity-based protein profiling. Topics in Current Chemistry. Springer, Berlin, Heidelberg. doi: 10.1007/128-2011-XXX
92. Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298:1912-1934 (Pubitemid 35425239)
93. Elphick LM, Lee SE, Gouverneur V et al (2007) Using chemical genetics and ATP analogs to dissect protein kinase function. ACS Chem Biol 2:299-314 (Pubitemid 350001578)
94. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187 (Pubitemid 41058349)
95. Wymann MP, Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17:141-149 (Pubitemid 40380937)
96. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805 (Pubitemid 38374863)
97. Fedorov O, Marsden B, Pogacic V et al (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 104:20523-20528
98. Fedorov O, Sundstrom M, Marsden B et al (2007) Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov Today 12:365-372 (Pubitemid 46636375)
99. Hanks SK, Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9:576-596
100. Zheng J, Knighton DR, ten Eyck LF et al (1993) Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 32:2154-2161 (Pubitemid 23094874)
101. Patricelli MP, Szardenings AK, Liyanage M et al (2007) Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46:350-358 (Pubitemid 46105428)
102. Arcaro A, Wymann MP (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 296(Pt 2):297-301 (Pubitemid 23350826)
103. Yano H, Nakanishi S, Kimura K et al (1993) Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 268:25846-25856 (Pubitemid 23358203)
104. Breinbauer R et al. (2012) Activity Based Protein Profiling for Natural Product Target Discovery. Topics in Current Chemistry. Springer, Berlin, Heidelberg. doi: 10.1007/128-2011-XXX
105. Gupta V, Ogawa AK, Du X et al (1997) A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A. J Med Chem 40:3199-3206 (Pubitemid 27413744)
106. Zhou L, Yu H, Chen K (2002) Relationship between microcystin in drinking water and colorectal cancer. Biomed Environ Sci 15:166-171
107. Goldberg J, Huang HB, Kwon YG et al (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376:745-753
108. Shreder KR, Liu Y, Nomanhboy T et al (2004) Design and synthesis of AX7574: a microcystin-derived, fluorescent probe for serine/threonine phosphatases. Bioconjug Chem 15:790-798 (Pubitemid 38981953)
109. Lo LC, Pang TL, Kuo CH et al (2002) Design and synthesis of class-selective activity probes for protein tyrosine phosphatases. J Proteome Res 1:35-40
110. Kumar S, Zhou B, Liang F et al (2004) Activity-based probes for protein tyrosine phosphatases. Proc Natl Acad Sci USA 101:7943-7948 (Pubitemid 38698033)
111. Zechel DL, Withers SG (2000) Glycosidase mechanisms: anatomy of a finely tuned catalyst. Acc Chem Res 33:11-18
112. Tsai CS, Li YK, Lo LC (2002) Design and synthesis of activity probes for glycosidases. Org Lett 4:3607-3610
113. Wicki J, Rose DR, Withers SG (2002) Trapping covalent intermediates on beta-glycosidases. Methods Enzymol 354:84-105
114. Vocadlo DJ, Bertozzi CR (2004) A strategy for functional proteomic analysis of glycosidase activity from cell lysates. Angew Chem Int Ed Engl 43:5338-5342 (Pubitemid 39433912)
115. Vocadlo DJ, Hang HC, Kim EJ et al (2003) A chemical approach for identifying O-GlcNAcmodified proteins in cells. Proc Natl Acad Sci USA 100:9116-9121 (Pubitemid 37033892)
116. Denisov IG, Makris TM, Sligar SG et al (2005) Structure and chemistry of cytochrome P450. Chem Rev 105:2253-2277 (Pubitemid 40951784)
117. Guengerich FP, Wu ZL, Bartleson CJ (2005) Function of human cytochrome P450s: characterization of the orphans. Biochem Biophys Res Commun 338:465-469 (Pubitemid 41540591)
118. Hughes AL, Powell DW, Bard M et al (2007) Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 5:143-149 (Pubitemid 46172917)
119. Aguiar M, Masse R, Gibbs BF (2005) Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev 37:379-404 (Pubitemid 40677509)
120. Wright AT, Cravatt BF (2007) Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo. Chem Biol 14:1043-1051 (Pubitemid 47404904)
121. Wright AT, Song JD, Cravatt BF (2009) A suite of activity-based probes for human cytochrome P450 enzymes. J Am Chem Soc 131:10692-10700
122. Jones JE, Causey CP, Knuckley B et al (2009) Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr Opin Drug Discov Devel 12:616-627
123. Vossenaar ER, van Venrooij WJ (2004) Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 6:107-111 (Pubitemid 38735665)
124. Luo Y, Arita K, Bhatia M et al (2006) Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45:11727-11736 (Pubitemid 44497800)
125. Luo Y, Knuckley B, Lee YH et al (2006) A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc 128:1092-1093 (Pubitemid 43190618)
126. Stone EM, Schaller TH, Bianchi H et al (2005) Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase. Biochemistry 44:13744-13752 (Pubitemid 41507455)
127. Slack JL, Causey CP, Luo Y et al (2011) Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem Biol 6:466-476
128. Luo Y, Knuckley B, Bhatia M et al (2006) Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc 128:14468-14469 (Pubitemid 44749840)
129. Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847 (Pubitemid 26255262)
130. Bogyo M, McMaster JS, Gaczynska M et al (1997) Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci USA 94:6629-6634
131. Bochtler M, Ditzel L, GrollMet al (1999) The proteasome. Annu Rev Biophys Biomol Struct 28:295-317 (Pubitemid 29319261)
132. Jackson G, Einsele H, Moreau P et al (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 31:591-602 (Pubitemid 41662886)
133. Richardson PG, Mitsiades C, Hideshima T et al (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47 (Pubitemid 43261977)
134. Meng L, Kwok BH, Sin N et al (1999) Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 59:2798-2801 (Pubitemid 29283111)
135. Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407-419 (Pubitemid 41579835)
136. Baumeister W, Walz J, Zuhl F et al (1998) The proteasome: paradigm of a selfcompartmentalizing protease. Cell 92:367-380
137. Verdoes M, Florea BI, Menendez-Benito V et al (2006) A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol 13:1217-1226 (Pubitemid 44750733)
138. Verdoes M, Willems LI, van der Linden WA et al (2010) A panel of subunit-selective activity-based proteasome probes. Org Biomol Chem 8:2719-2727
139. Geurink PP, Florea BI, Van der Marel GA et al (2010) Probing the proteasome cavity in three steps: bio-orthogonal photo-reactive suicide substrates. Chem Commun (Camb) 46:9052-9054
140. Spannhoff A, Sippl W, Jung M (2009) Cancer treatment of the future: inhibitors of histone methyltransferases. Int J Biochem Cell Biol 41:4-11
141. Ryu H, Lee J, Hagerty SW et al (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci USA 103:19176-19181 (Pubitemid 350002846)
142. Berdasco M, Ropero S, Setien F et al (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 106:21830-21835
143. Kurotaki N, Imaizumi K, Harada N et al (2002) Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30:365-366
144. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705 (Pubitemid 46273577)
145. Smith BC, Denu JM (2009) Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789:45-57
146. Cole PA (2008) Chemical probes for histone-modifying enzymes. Nat Chem Biol 4:590-597
147. Chuikov S, Kurash JK, Wilson JR et al (2004) Regulation of p53 activity through lysine methylation. Nature 432:353-360 (Pubitemid 39551664)
148. Huang J, Perez-Burgos L, Placek BJ et al (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature 444:629-632 (Pubitemid 44864441)
149. Subramanian K, Jia D, Kapoor-Vazirani P et al (2008) Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell 30:336-347 (Pubitemid 351615317)
150. Lee JS, Kim Y, Kim IS et al (2010) Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell 39:71-85
151. Binda O, Boyce M, Rush JS et al (2011) A chemical method for labeling lysine methyltransferase substrates. Chembiochem 12:330-334
152. Islam K, Zheng W, Yu H et al (2011) Expanding cofactor repertoire of protein lysine methyltransferase for substrate labeling. ACS Chem Biol 6(7):679-684
153. Peters W, Willnow S, Duisken M et al (2010) Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling. Angew Chem Int Ed Engl 49:5170-5173
154. Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823-833 (Pubitemid 350006257)
155. Tachibana M, Sugimoto K, Fukushima T et al (2001) Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 276:25309-25317
156. Rathert P, Dhayalan A, Murakami M et al (2008) Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol 4:344-346 (Pubitemid 351693993)
157. Wozniak RJ, Klimecki WT, Lau SS et al (2007) 5-Aza-20-deoxycytidine- mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26:77-90 (Pubitemid 46067333)
158. Wang R, Zheng W, Yu H et al (2011) Labeling substrates of protein arginine methyltransferase with engineered enzymes and matched S-adenosyl-L-methionine analogues. J Am Chem Soc 133:7648-7651
159. Shah K, Liu Y, Deirmengian C et al (1997) Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci USA 94:3565-3570 (Pubitemid 27180412)
160. Liu Y, Shah K, Yang F et al (1998) Engineering Src family protein kinases with unnatural nucleotide specificity. Chem Biol 5:91-101 (Pubitemid 28199138)
161. Bishop AC, Ubersax JA, Petsch DT et al (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407:395-401
162. Adam GC, Cravatt BF, Sorensen EJ (2001) Profiling the specific reactivity of the proteome with non-directed activity-based probes. Chem Biol 8:81-95 (Pubitemid 32165814)
163. Barglow KT, Cravatt BF (2004) Discovering disease-associated enzymes by proteome reactivity profiling. Chem Biol 11:1523-1531 (Pubitemid 39527279)
164. Barglow KT, Cravatt BF (2006) Substrate mimicry in an activity-based probe that targets the nitrilase family of enzymes. Angew Chem Int Ed Engl 45:7408-7411 (Pubitemid 44786970)
165. Rhee SG (2006) Cell signaling. H2O2, a necessary evil for cell signaling. Science 312:1882-1883 (Pubitemid 43993698)
166. Terada LS (2006) Specificity in reactive oxidant signaling: think globally, act locally. J Cell Biol 174:615-623
167. D'Autreaux B, Toledano MB (2007) ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8:813-824 (Pubitemid 47462134)
168. Poole LB, Nelson KJ (2008) Discovering mechanisms of signaling-mediated cysteine oxidation. Curr Opin Chem Biol 12:18-24
169. Reddie KG, Carroll KS (2008) Expanding the functional diversity of proteins through cysteine oxidation. Curr Opin Chem Biol 12:746-754
170. Benitez LV, Allison WS (1974) The inactivation of the acyl phosphatase activity catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate dehydrogenase by dimedone and olefins. J Biol Chem 249:6234-6243
171. Leonard SE, Garcia FJ, Goodsell DS et al (2011) Redox-based probes for protein tyrosine phosphatases. Angew Chem Int Ed Engl 50:4423-4427
172. Leonard SE, Reddie KG, Carroll KS (2009) Mining the thiol proteome for sulfenic acid modifications reveals new targets for oxidation in cells. ACS Chem Biol 4:783-799
173. Jessani N, Young JA, Diaz SL et al (2005) Class assignment of sequence-unrelated members of enzyme superfamilies by activity-based protein profiling. Angew Chem Int Ed Engl 44:2400-2403 (Pubitemid 40600225)
174. Hayes BK, Varki A (1989) O-acetylation and de-O-acetylation of sialic acids. Sialic acid esterases of diverse evolutionary origins have serine active sites and essential arginine residues. J Biol Chem 264:19443-19448 (Pubitemid 19285856)
175. Li YM, Xu M, Lai MT et al (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689-694 (Pubitemid 30428655)
176. Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269-270
177. Christofk HR, Vander Heiden MG, Wu N et al (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181-186 (Pubitemid 351380242)
178. Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744
179. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777 (Pubitemid 47469806)
180. Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6:764-775 (Pubitemid 44450465)
181. Ramos-DeSimone N, Hahn-Dantona E, Sipley J et al (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076
182. Jessani N, Niessen S, Mueller BM et al (2005) Breast cancer cell lines grown in vivo: what goes in isn't always the same as what comes out. Cell Cycle 4:253-255 (Pubitemid 41365329)
183. Joyce JA, Baruch A, Chehade K et al (2004) Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5:443-453 (Pubitemid 38610246)
184. Taubes G (2008) The bacteria fight back. Science 321:356-361
185. Heal WP, Tate EW (2012) On the Applications of Activity-Based Protein Profiling to Microbial Pathogenesis. Topics in Current Chemistry. Springer, Berlin, Heidelberg. doi: 10.1007/128-2011-299
186. Blum G, von Degenfeld G, Merchant MJ et al (2007) Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 3:668-677 (Pubitemid 47417706)
187. Jedeszko C, Sloane BF (2004) Cysteine cathepsins in human cancer. Biol Chem 385:1017-1027 (Pubitemid 39600309)
188. Harbeck N, Alt U, Berger U et al (2001) Prognostic impact of proteolytic factors (urokinasetype plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757-2764 (Pubitemid 32911381)
189. Foekens JA, Kos J, Peters HA et al (1998) Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16:1013-1021 (Pubitemid 28108735)
190. Rayo J, Amara N, Krief P et al (2011) Live cell labeling of native intracellular bacterial receptors using aniline-catalyzed oxime ligation. J Am Chem Soc 133(19):7469-7475
191. Krysiak J, Breinbauer R (2012) Activity-based protein profiling for natural product target discovery. Topics in Current Chemistry. Springer, Berlin, Heidelberg. doi: 10.1007/128-2011-289
192. Bulaj G, Kortemme T, Goldenberg DP (1998) Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry 37:8965-8972 (Pubitemid 28299665)
193. Lewis CT, Seyer JM, Carlson GM (1989) Cysteine 288: an essential hyperreactive thiol of cytosolic phosphoenolpyruvate carboxykinase (GTP). J Biol Chem 264:27-33 (Pubitemid 19027570)
194. Knowles JR (1976) The intrinsic pKa-values of functional groups in enzymes: improper deductions from the pH-dependence of steady-state parameters. CRC Crit Rev Biochem 4:165-173
195. Weerapana E, Wang C, Simon GM et al (2010) Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468:790-795